Literature DB >> 24957821

Micafungin at physiological serum concentrations shows antifungal activity against Candida albicans and Candida parapsilosis biofilms.

M Guembe1, J Guinea2, L J Marcos-Zambrano3, A Fernández-Cruz3, T Peláez4, P Muñoz4, E Bouza4.   

Abstract

We assessed the in vitro activity of micafungin against preformed Candida biofilms by measuring the concentration of drug causing the most fungal damage and inhibition of regrowth. We studied 37 biofilm-producing Candida spp. strains from blood cultures. We showed that micafungin was active against planktonic and sessile forms of Candida albicans strains and moderately active against Candida parapsilosis sessile cells. Concentrations of micafungin above 2 μg/ml were sufficiently high to inactivate regrowth of Candida sessile cells.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24957821      PMCID： PMC4135876          DOI： 10.1128/AAC.02738-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  42 in total

1.  National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System.

Authors: 
Journal:  Am J Infect Control       Date:  1999-12       Impact factor: 2.918

2.  Evolution and aetiological shift of catheter-related bloodstream infection in a whole institution: the microbiology department may act as a watchtower.

Authors:  M Rodríguez-Créixems; P Muñoz; P Martín-Rabadán; E Cercenado; M Guembe; E Bouza
Journal:  Clin Microbiol Infect       Date:  2013-04-09       Impact factor: 8.067

3.  Hospital-acquired candidemia. The attributable mortality and excess length of stay.

Authors:  S B Wey; M Mori; M A Pfaller; R F Woolson; R P Wenzel
Journal:  Arch Intern Med       Date:  1988-12

4.  Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms.

Authors:  G Ramage; K Vande Walle; B L Wickes; J L López-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

5.  In vitro method to study antifungal perfusion in Candida biofilms.

Authors:  Y H Samaranayake; J Ye; J Y Y Yau; B P K Cheung; L P Samaranayake
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

6.  Penetration of Candida biofilms by antifungal agents.

Authors:  Mohammed A Al-Fattani; L Julia Douglas
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates.

Authors:  Maria Simitsopoulou; Pavla Peshkova; Efthymia Tasina; Aspasia Katragkou; Daniela Kyrpitzi; Aristea Velegraki; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

8.  Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital.

Authors:  Jorge Garbino; Lenka Kolarova; Peter Rohner; Daniel Lew; Peter Pichna; Didier Pittet
Journal:  Medicine (Baltimore)       Date:  2002-11       Impact factor: 1.889

9.  A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade.

Authors:  A M Tortorano; A Prigitano; C Lazzarini; M Passera; M L Deiana; S Cavinato; C De Luca; A Grancini; G Lo Cascio; C Ossi; E Sala; M T Montagna
Journal:  Infection       Date:  2013-04-05       Impact factor: 3.553

10.  Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital.

Authors:  Mario Tumbarello; Barbara Fiori; Enrico Maria Trecarichi; Patrizia Posteraro; Angela Raffaella Losito; Alessio De Luca; Maurizio Sanguinetti; Giovanni Fadda; Roberto Cauda; Brunella Posteraro
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240
View more
  6 in total

1.  In vitro activity of micafungin against biofilms of Candida albicans, Candida glabrata, and Candida parapsilosis at different stages of maturation.

Authors:  Małgorzata Prażyńska; Tomasz Bogiel; Eugenia Gospodarek-Komkowska
Journal:  Folia Microbiol (Praha)       Date:  2017-10-05       Impact factor: 2.099

2.  Pharmacodynamic and Immunomodulatory Effects of Micafungin on Host Responses against Biofilms of Candida parapsilosis in Comparison to Those of Candida albicans.

Authors:  Maria Simitsopoulou; Katerina Chlichlia; Daniela Kyrpitzi; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

3.  Association of different Candida species with catheter-related candidemia, and the potential antifungal treatments against their adhesion properties and biofilm-forming capabilities.

Authors:  Xiao-Shu Zuo; Yanan Liu; Xuan Cai; Liying Zhan; Ke Hu
Journal:  J Clin Lab Anal       Date:  2021-02-19       Impact factor: 2.352

4.  Micafungin in the treatment of candiduria: A case series.

Authors:  Lauren E Kane; Katie M Muzevich
Journal:  Med Mycol Case Rep       Date:  2016-01-30

5.  Candidacidal Activity of Selected Ceragenins and Human Cathelicidin LL-37 in Experimental Settings Mimicking Infection Sites.

Authors:  Bonita Durnaś; Urszula Wnorowska; Katarzyna Pogoda; Piotr Deptuła; Marzena Wątek; Ewelina Piktel; Stanisław Głuszek; Xiaobo Gu; Paul B Savage; Katarzyna Niemirowicz; Robert Bucki
Journal:  PLoS One       Date:  2016-06-17       Impact factor: 3.240

Review 6.  The Role of Antifungals against Candida Biofilm in Catheter-Related Candidemia.

Authors:  Emilio Bouza; Jesús Guinea; María Guembe
Journal:  Antibiotics (Basel)       Date:  2014-12-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.